Akebia Therapeutics, Inc.
As of Oct 22, 2026, Akebia Therapeutics is in Stage 4, the downtrend phase, now in week 8 (since Aug 28, 2026). It closed at $0.56, 82.3% below its 52-week high and below its 200-day average, which is falling.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AKBA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AKBA among Drug Manufacturers - Specialty & Generic74th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …74 | AKBA | Stage 4 · wk 8 | 10 | −39.8% |
Akebia Therapeutics: quick answers
What stage is Akebia Therapeutics in?
As of Oct 22, 2026, Akebia Therapeutics (AKBA) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 28, 2026 and is in week 8. What the four stages mean
Is Akebia Therapeutics in an uptrend?
No. Akebia Therapeutics is in a Stage 4 downtrend. It trades 52.0% below its 200-day average, which is falling.
How far is Akebia Therapeutics from its 52-week high?
Akebia Therapeutics closed at $0.56 on Oct 22, 2026, 82.3% below its 52-week high of $3.17. Its 52-week low is $0.56.
How has Akebia Therapeutics performed over the past year?
As of Oct 22, 2026, Akebia Therapeutics is down 82.0% over the past year and down 63.7% so far in 2026.
Which sector and industry is Akebia Therapeutics in?
Akebia Therapeutics is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.